12:00 AM
 | 
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AVX-470: Phase Ib started

Avaxia began a double-blind, placebo-controlled, international Phase Ib trial to evaluate 0.2, 1.6 and 3.5 g oral AVX-470 daily for 28 days in about...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >